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Abstract
Background: Circulating inflammatory markers may more strongly relate to risk of fatal versus nonfatal cardiovascular
disease (CVD) events, but robust prospective evidence is lacking. We tested whether interleukin (IL)-6, C-reactive protein
(CRP), and fibrinogen more strongly associate with fatal compared to nonfatal myocardial infarction (MI) and stroke.
Methods and Findings: In the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), baseline inflammatory
markers in up to 5,680 men and women aged 70–82 y were related to risk for endpoints; nonfatal CVD (i.e., nonfatal MI and
nonfatal stroke [n=672]), fatal CVD (n=190), death from other CV causes (n=38), and non-CVD mortality (n=300), over 3.2-
y follow-up. Elevations in baseline IL-6 levels were significantly (p=0.0009; competing risks model analysis) more strongly
associated with fatal CVD (hazard ratio [HR] for 1 log unit increase in IL-6 1.75, 95% confidence interval [CI] 1.44–2.12) than
with risk of nonfatal CVD (1.17, 95% CI 1.04–1.31), in analyses adjusted for treatment allocation. The findings were consistent
in a fully adjusted model. These broad trends were similar for CRP and, to a lesser extent, for fibrinogen. The results were
also similar in placebo and statin recipients (i.e., no interaction). The C-statistic for fatal CVD using traditional risk factors was
significantly (+0.017; p,0.0001) improved by inclusion of IL-6 but not so for nonfatal CVD events (p=0.20).
Conclusions: In PROSPER, inflammatory markers, in particular IL-6 and CRP, are more strongly associated with risk of fatal
vascular events than nonfatal vascular events. These novel observations may have important implications for better
understanding aetiology of CVD mortality, and have potential clinical relevance.
Please see later in the article for the Editors’ Summary.
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Low-grade chronic inflammation is now widely thought to play
an important role in the process of atherogenesis [1], and levels of
inflammatory markers such as C-reactive protein (CRP) [2],
interleukin (IL)-6 [3], and fibrinogen [4] are moderately associated
with risk of coronary heart disease (CHD) events. Recently we
reported that whilst CRP was associated with subsequent
combined nonfatal and fatal vascular events in the elderly at risk,
the C-statistic was moderately (albeit significantly) increased with
addition of CRP to traditional risk factors [5]. Other studies have
reported similar findings in that all inflammatory markers appear
to have moderate associations with risk of CHD events [6,7], and
provide minimal clinical utility to the C-statistic in risk scores [8–
10].
Often in epidemiological studies, fatal and nonfatal cardiovas-
cular disease (CVD) events are combined for the purposes of
increasing power in a single endpoint. Obviously these CVD
events share common aetiology, but the question may be asked as
to whether the nature of the event differs only in severity or
whether there are subtle differences in underlying mechanisms
that lead to fatal events versus nonfatal outcomes. Insensitivities to
such clinically important questions in many reports through study
design, limited endpoint acquisition, and analysis may be one
reason that acute phase response-associated inflammatory risk
markers predict CVD events moderately in many prospective
studies.
Comprehensive investigation of these questions is required to
extend trends noted, but rarely commented upon, in other studies.
For instance, in the Scottish Heart Health Study, plasma
fibrinogen showed at least as strong an association with total
mortality as with risk of CHD [11], a finding subsequently
confirmed in the Fibrinogen Studies Collaboration [4]. Similar
findings have been reported for blood viscosity (of which
fibrinogen is a determinant) [12], IL-6, and CRP [13–20]. These
potential differences and their implications are not widely
appreciated by the vascular community. Additionally, simulta-
neous and comprehensive investigation of associations of these
separate endpoints, including in particular separation of fatal and
nonfatal CVD, with a range of inflammatory markers is required
but is lacking. Potential differences may have implications both for
our understanding of the role of inflammation in CVD aetiology,
and for the development of future risk scores based on risk for fatal
CVD events.
In PROSPER [21], a clinical trial of pravastatin in the elderly at
risk, with more than 850 incident CVD events including 190 fatal
CVD events, we had the potential to explore for differential
associations of IL-6, CRP, and fibrinogen with subsequent
prespecified vascular events (fatal versus nonfatal), as well as
examine whether such associations were independent of tradition-
al risk factors.
Methods
The protocol of PROSPER has been published elsewhere
[21,22], and the methodology and outcome of the main trial has
also been published [22].
Participants
Between December 15, 1997, and May 7, 1999, we screened
and enrolled individuals from Scotland, Ireland, and The
Netherlands. Briefly, men and women aged 70–82 y were
recruited if they had either preexisting vascular disease (coronary,
cerebral, or peripheral) or increased risk of such disease because of
smoking, hypertension, or diabetes. Their plasma total cholesterol
was required to be 4.0–9.0 mmol/l and their triglyceride
concentrations less than 6.0 mmol/l. After screening, eligible
individuals entered a 4-wk single-blind placebo lead-in period,
those who used ,75% or .120% of the placebo medication were
excluded. The institutional ethics review boards of all centres
approved the protocol, and all participants gave written informed
consent. The protocol was consistent with the Declaration of
Helsinki.
Protocol
Individuals were randomized to receive either pravastatin
40 mg daily or matching placebo [21].We reviewed participants
every 3 mo, with a mean of 3.2-y follow-up. Lipoprotein profiles
were measured at the Centre for Disease Control-certified central
lipoprotein laboratory in Glasgow. All data were processed and
analysed at the study data centre in The Robertson Centre for
Biostatistics, Glasgow.
The outcomes of the present analyses were predefined as: (1)
nonfatal CVD: combined endpoints of nonfatal myocardial
infarction (MI) and nonfatal stroke (comprises infarcts and
haemorrhages); (2) fatal CVD: definite or suspect death from
CHD or stroke (comprises infarcts and haemorrhages); (3) fatal
other CVD: definite or suspect death from ‘‘other’’ CVD causes
(aneurysm, pulmonary embolism, heart failure); (4) non-CVD
mortality: death from non-CVD causes.
For CVD events only the first event was included (i.e., deaths
preceded by a nonfatal event were excluded and participants were
censored at date of nonfatal event). All endpoints were validated
by a blinded events committee.
Laboratory Aspects
Baseline lipids, blood pressure, and body mass index (BMI) were
measured as previously reported [21,22]. IL-6 was assayed on a
saved biobank of baseline samples in 2007 using a high-sensitivity
ELISA (R& D Systems) with inter- and intra-assay CVs of ,6%
and a sensitivity of ,0.16 pg/ml. CRP was measured as detailed
previously [5] on an assay with a sensitivity of ,0.17 mg/dl and
with inter- and intra-assay CVs of ,5%. Fibrinogen was
determined by the Clauss method on an MDA 180 coagulometer
(Trinity Biotech) and using the 9th British Standard to calibrate
(NIBSC), with intra- and inter-assay CVs of ,4%. All samples
were processed by technicians blinded to the identity of samples,
and results entered into a master database, which the PROSPER
statistics division in Scotland (Robertson Centre, University of
Glasgow) is custodian of.
Statistical Analysis
The distribution of IL-6 (pg/ml) and CRP (mg/dl) was
positively skewed and a logarithmic transformation was used.
Baseline characteristics were compared between participants with
and without the primary endpoint (as defined in original study)
using the two-sample t-test for continuous variables and the chi-
squared test for categorical variables. The influence of IL-6, CRP,
and fibrinogen on the endpoints of interest—extended herein to
include nonfatal CVD events, fatal CVD events, fatal other CV
events, or non-CVD death—were investigated using Kaplan-
Meier curves (for IL-6) and Cox proportional hazards models,
adjusting for randomized treatment and baseline covariates
(continuous variables: age, low-density lipoprotein [LDL] choles-
terol, high-density lipoprotein [HDL] cholesterol, blood pressure,
BMI, log triglyceride; categorical variables: gender, country,
smoking status, history of diabetes, use of antihypertensive
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[PAD], and history of stroke or TIA). Log IL-6, log CRP, and
fibrinogen were analysed by 1-unit increments within the
population, and hence represent a continuous measure, providing
maximum power for detecting an association. Results are reported
as number (percentage [%]) of events and hazard ratio (HR) of a
given endpoint (95% confidence interval [CI]) for each unit
increment. The validity of the proportional hazards assumption
was assessed by plots of Cox-Snell residuals and Martingale
residuals with no evidence of significant departures observed. In
addition, IL-6 associations with endpoints were also analysed by
comparing extreme thirds of the population based on IL-6
expression in the whole cohort. A similar method was previously
reported for CRP [3]. A competing risks model was constructed to
test the difference in the HRs for nonfatal versus fatal CVD events.
The model combined nonfatal CVD and fatal CVD events, and
treated all other deaths as censored [23,24]. C-statistics (analogous
to the area under the ROC curve) were calculated for Cox
proportional hazards survival models and with and without
adjustment for log IL-6 or CRP as continuous measures and are
reported for selected models, along with probability values testing
whether the inclusion of log IL-6 or CRP lead to predictions that
are more concordant with observed events. Summary statistics are
reported as mean (standard deviation [SD]) for continuous
variables and number (%) for categorical variables. A p-value of
,0.05 was considered significant.
Results
Plasma IL-6 levels were obtained in 5,653 biobank samples
(97.4%) of the original 5,804 patients. Of these, 667 (11.8%) had a
nonfatal CVD event, 189 (3.3%) had a fatal CVD event, 37 (0.7%)
died from other CVD causes (including 18 aneurysms, seven
pulmonary embolisms, and three heart failures), and a further 299
(5.3%) had non-CVD deaths. Corresponding samples measured
for CRP were 5,680 samples, 672 nonfatal CVD events, 190 fatal
CVD events, 38 fatal other CVD events, and 300 non-CVD
deaths. Fibrinogen was measured in 5,631 individuals. All other
risk factor measurements were available in all individuals. 59
patients who had an incident nonfatal CVD went on to die from
other events (vascular or otherwise). For the purpose of the present
analysis, only the first event was included.
Baseline characteristics of participants who did and did not
have a primary endpoint (defined in the original trial [22] and
previous CRP analysis [5] as ‘‘CHD or stroke death or nonfatal
MI or stroke’’) are shown in Table 1. This table shows results
broadly expected in an elderly at risk cohort, with significant
differences between cases and noncases (i.e., those without an
event) in many (but not all) conventional risk factors.
Participants who had a primary vascular event during study
follow-up were slightly older (6 mo on average), more likely to
be male, and to have a history of diabetes, CHD, peripheral
arterial disease, stroke or TIA, but less likely to have been taking
pravastatin. Baseline HDL cholesterol, but not triglyceride or
LDL cholesterol, were lower among subsequent cases. As
expected, levels of IL-6 and CRP were also higher among the
case than control population. Fibrinogen levels were not
significantly different in the primary endpoint group. IL-6
concentrations were generally higher than levels seen in other
middle-aged cohorts [3], but levels are in keeping with older age
groups from a general population cross sectional study [25],
which is commensurate with the current cohort’s general age
and state of health. The same was broadly true for CRP and
fibrinogen [25].
Associations of Elevated Inflammatory Markers with
Primary Combined Nonfatal and Fatal Endpoints in the
Cohort
When considering primary endpoints (including both fatal or
nonfatal CVD events) comparing extreme thirds of the population
in terms of plasma IL-6 levels after adjusting for only randomized
treatment allocation gave an HR of 1.42 (95% CI 1.20–1.67).
After adjusting for treatment allocation, age, gender, baseline LDL
cholesterol, HDL cholesterol, triglycerides, systolic and diastolic
blood pressure, current or exsmoker, BMI, diabetes, use of
antihypertensive therapy, and country, the HR was attenuated to
1.20 (CI 1.01–1.42) comparing extreme thirds, and 1.10 (CI 1.03–
1.18) for a 1-unit increase in log IL-6. As expected from results in
Table 1, fibrinogen showed no significant association with risk of a
primary endpoint (unpublished data). Associations of CRP with
the primary endpoint have been previously reported [5].
Dissecting Associations of Inflammatory Markers with
Fatal and Nonfatal Events
We subsequently examined associations with risk for more
specifically defined endpoints. Importantly, there was no differ-
ence in risk of any of the endpoints whether participants were
randomized to pravastatin or placebo (see Table 2), allowing us to
combine all study participants for the purposes of this analysis.
Furthermore, there was no significant interaction with history of
vascular disease at baseline (unpublished data). Nevertheless,
existing CVD was adjusted for in full adjustment model.
Figure 1A–1D shows the Kaplan-Meier curves for cumulative
percentage of events in the cohort by thirds of IL-6 expression for
endpoints of nonfatal CVD, fatal CVD, fatal other CVD, and
non-CV mortality. These curves clearly show that while thirds of
IL-6 showed little discriminative ability in separating risk for
nonfatal CVD in unadjusted models (p=0.13), associations with
risk for fatal CVD events, fatal other CV events, or non-CVD
mortality were all highly significant (p#0.0002 for all). Curves for
CRP and fibrinogen showed broadly similar patterns (unpub-
lished data), although IL-6 data showed clearest separation of
curves.
Thereafter, HRs for associations of inflammatory markers with
each of the four endpoint groups were assessed using continuous
measures (to retain maximum power) without and with adjustment
for all conventional risk factors plus other possible confounders
(adjusted model detailed in Figure 2). As can be seen clearly, the
HR for association of elevation in IL-6 with risk for nonfatal CVD
of 1.06 (95% CI 0.94–1.20) was weaker than each of the mortality
endpoints, as the upper confidence limits were less than the lower
confidence limits of each of the mortality endpoints: HR 1.58
(1.28–1.94) for fatal CVD, 2.02 (1.28–3.18) for fatal other CV
events, and 1.47 (1.24–1.74) for non-CVD death. Broadly similar
associations were noted for CRP. For fibrinogen, there was no
significant association with risk of nonfatal CVD, but borderline
significant associations were evident with each of the CVD
mortality endpoints (Table 3). Competing risk models combining
nonfatal CVD and fatal CVD events were then constructed to
formally test the differences in HRs for IL-6, CRP, and fibrinogen.
For models adjusting for randomized treatment the HRs for fatal
CVD were found to be significantly higher (x
2 for heterogene-
ity=14.1, p=0.0009; x
2=12.0, p=0.0025; x
2=8.7, p=0.013 for
IL-6, CRP, and fibrinogen, respectively). Significant differences
were also observed for fully adjusted models. Finally, we checked
whether white cell count also showed the same pattern as the other
three inflammatory markers and once again noted much stronger
associations with fatal CVD events (data on request).
Inflammation: Fatal vs Nonfatal CVD Events
PLoS Medicine | www.plosmedicine.org 3 June 2009 | Volume 6 | Issue 6 | e1000099Prediction of Fatal and Nonfatal CVD Events
We explored what the differing associations of inflammatory
markers with risk of fatal versus nonfatal CVD events might mean
for risk prediction by constructing C-statistics relating to the
predictive ability of traditional risk factors with and without IL-6
and CRP for the clinically relevant endpoints of nonfatal CVD,
Table 1. Baseline characteristics by incident primary combined nonfatal and fatal endpoint (p-value versus no event group).
Variable Characteristic Primary Endpoint (n=861) No Event (n=4,792) p-Value
Continuous variables, mean (SD) Age (y) 75.8 (3.5) 75.3 (3.3) ,0.0001
BMI (kg/m
2) 26.9 (4.1) 26.8 (4.2) 0.52
Systolic blood pressure (mmHg) 155.2 (22.8) 154.5 (21.6) 0.42
Diastolic blood pressure (mmHg) 82.9 (11.8) 83.9 (11.3) 0.025
Total cholesterol (mmol/l) 5.62 (0.87) 5.69 (0.91) 0.037
HDL cholesterol (mmol/l) 1.24 (0.34) 1.29 (0.35) ,0.0001
LDL cholesterol (mmol/l) 3.76 (0.76) 3.79 (0.80) 0.19
Triglyceride (mmol/l)
a 1.44 (1.53) 1.41 (1.51) 0.14
IL-6 (pg/ml)
a 2.91 (1.93) 2.61 (1.92) ,0.0001
CRP (mg/l)
a 3.64 (3.08) 3.01 (3.05) ,0.0001
Fibrinogen (g/l) 3.62 (0.75) 3.59 (0.73) 0.31
Categorical variables, n (%) Pravastatin 399 (46.3) 2,415 (50.4) 0.028
Male 492 (57.1) 2,234 (46.6) ,0.0001
Smoking 0.088
Never 267 (31.0) 1,649 (34.4)
Current smoker 229 (26.6) 1,283 (26.8)
Exsmoker 365 (42.4) 1,860 (38.8)
Country ,0.0001
Scotland 362 (42.0) 2,109 (44.0)
Ireland 382(44.4) 1,750 (36.5)
Netherlands 117 (13.6) 933 (19.5)
History of: Diabetes 129 (15.0) 474 (9.9) ,0.0001
Hypertension 518 (60.2) 2,993 (62.2) 0.27
Coronary disease 378 (43.9) 1,428 (29.8) ,0.0001
Peripheral arterial disease 137 (15.9) 492 (10.3) ,0.0001
Stroke or TIA 125 (14.5) 510 (10.6) 0.0009
Any vascular disease 488 (56.7) 2,011 (42.0) ,0.0001
Please note that because of the design structure of the trial—recruiting more participants with hypertension/smokers and diabetes (and women) into the low risk
primary prevention group—the significance or nonsignificance of univariate comparisons in this table could be potentially misleading. p-Values for continuous variables
are from two-sample t-test and for categorical variables from chi-squared test.
aValues are geometric means (SD) calculated from the log-transformed distribution and the (p-value).
SD, standard deviation; TIA, transient ischemic attack.
doi:10.1371/journal.pmed.1000099.t001
Table 2. Associations of IL-6, CRP, and fibrinogen (HR for 1-unit increase in log IL-6, log CRP, and fibrinogen) of experiencing one
of four categories of events by baseline treatment allocation.
Endpoints IL-6 HR (95% CI) CRP (HR 95% CI) Fibrinogen (HR 95% CI)
Placebo
(n=2,839)
Pravastatin
(n=2,814) p-Value
Placebo
(n=2,853)
Pravastatin
(n=2,827) p-Value
Placebo
(n=2,819)
Pravastatin
(n=2,812) p-Value
Nonfatal CVD 1.19 (1.02–1.39) 1.10 (0.97–1.34) 0.73 1.17 (1.07–1.29) 1.04 (0.94–1.14) 0.08 1.01 (0.88–1.17) 0.97 (0.84–1.13) 0.72
Fatal CVD 1.68 (1.30–2.18) 1.81 (1.34–2.45) 0.78 1.35 (1.14–1.60) 1.42 (1.17–1.74) 0.74 1.29 (1.02–1.64) 138 (1.05–1.81) 0.78
Fatal other CV 2.04 (1.14–3.67) 2.49 (1.37–4.53) 0.64 1.64 (1.12–2.42) 1.76 (1.17–2.63) 0.81 1.23 (0.71–2.14) 1.80 (1.06–3.05) 0.34
Non-CVD
mortality
1.67 (1.33–2.10) 1.42 (1.14–1.77) 0.30 1.26 (1.08–1.46) 1.15 (1.00–1.32) 0.38 1.48 (1.22–1.79) 1.46 (1.21–1.77) 0.91
Event groupings as defined in the methods. Fatal CVD deaths preceded by nonfatal CVD are excluded. p-Value is for interaction between randomized treatment
allocation and marker. Unadjusted HR (95% CIs) are presented.
doi:10.1371/journal.pmed.1000099.t002
Inflammation: Fatal vs Nonfatal CVD Events
PLoS Medicine | www.plosmedicine.org 4 June 2009 | Volume 6 | Issue 6 | e1000099fatal CVD, and fatal other CVD. Conventional risk factors
predicted risk of fatal CVD (C-statistic 0.699) and fatal other CVD
(0.698) to a similar degree, although the predictive ability for
nonfatal CVD was lower (0.630). Addition of IL-6 to traditional
risk factors did not significantly increase discriminative predictive
ability in the nonfatal CVD group (p=0.20), although CRP did so
modestly (+0.003, p=0.023). However both IL-6 and CRP added
greater discriminative ability to the fatal CVD (+0.017 and +0.015;
both p,0.0001) and fatal other CVD groups (+0.047 and +0.075;
both p,0.0001) (full data on request).
Discussion
To our knowledge, this is the first study to directly and
simultaneously compare prospectively the associations of a range
of inflammatory markers separately with risks of fatal and nonfatal
CVD events in a hypothesis driven manner. The results show that
IL-6, CRP, and to a lesser extent, fibrinogen are more closely
linked to risk of fatal MI or stroke (i.e., fatal CVD) than to nonfatal
vascular events in the elderly at risk. In other words, we suggest
that inflammatory markers are linked more closely to risk of death
from CVD causes than to risk of nonfatal CVD events. We believe
our findings may be a key feature of the inflammatory-vascular risk
paradigm, which has been previously overlooked in the literature,
but one that may have both important biological, clinical, and
health implications.
PROSPER Results in Context of the Literature
Our key observation of a stronger link of inflammatory markers
with fatal CVD compared to nonfatal CVD significantly extends
suggestive (but inconclusive) observations from previous reports,
including studies in middle-aged and elderly individuals [4,11–
20,26,27], of potentially stronger associations between inflamma-
tory markers with CVD death. While the body of evidence from
these other studies has alluded to this possibility, our study is the
first we are aware of to systematically and simultaneously show
Figure 1. Kaplan-Meier time-to-event plots split by tertiles of IL-6 tertiles for (A) nonfatal CVD (n=667 events), (B) fatal CVD (n=189
deaths), (C) fatal other CV (n=37 deaths), and (D) non-CVD mortality (n=299 deaths).
doi:10.1371/journal.pmed.1000099.g001
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associated with fatal than nonfatal vascular events. We therefore
suggest that combining both fatal and nonfatal CVD events as a
single endpoint may make inappropriate assumptions about a
common aetiology, whereas in reality subtle but important
differences in risk factor patterns, perhaps particularly with regard
to inflammatory markers, exist.
Wenote that the significantly strongerassociation with fatalCVD
was particularly marked for IL-6 in PROSPER, which is a novel
observation. Our results for fibrinogen are consistent with and
significantly extend a previous report from the Fibrinogen Studies
Collaboration; the results section reports a borderline (p=0.05)
higher HR of 2.68 (95% CI 2.36–3.03) per 1 g/l increase in
fibrinogen for risk for fatal CHD compared with an HR of 2.30
(95% CI 2.10–2.52) for risk of a nonfatal MI [4], but there was no
further discussion on this finding. Interestingly, we found fibrinogen
to be the least discriminatory between fatal and nonfatal CVD, and
IL-6 to be most discriminatory. A similar collaborative meta-
analysis of individual prospective data for CRP did not explore such
differences, but does discuss the possibility of early publication bias
in the CRP literature [2]. Of note, earlier prospective studies for
CRP were more likely to include only fatal CVD endpoints than
later studies [15,16,19], perhaps helping to explain some of the
stronger associations seen for CRP with CVD outcomes in earlier
reports. Furthermore, this phenomenon may not be limited to
traditional inflammatory markers of the acute phase response. For
Figure 2. Plot showing associations of 1-unit increase in log IL-6, log CRP, and fibrinogen with HR of endpoints on a log scale (after
adjusting for randomized treatment, age, gender, LDL cholesterol, HDL cholesterol, triglycerides, BMI, systolic and diastolic blood
pressure, current and exsmoking, diabetes, previous CVD, use of antihypertensive therapy, and country).
doi:10.1371/journal.pmed.1000099.g002
Table 3. Associations of IL-6, CRP, and fibrinogen with risk (HR for 1-unit increase in log IL-6, log CRP, or fibrinogen) of
experiencing one of the four categories of events.
Inflammatory Marker Model
Nonfatal CVD
(n$667 Events)
Fatal CVD
(n$189 Deaths)
Fatal Other CV
(n$37 Deaths)
Non-CVD Mortality
(n$299 Deaths)
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
IL-6 (n=5,653) A 1.17 1.04–1.31 1.75 1.44–2.12 2.25 1.48–3.41 1.54 1.31–1.80
B 1.07 0.95–1.21 1.57 1.27–1.94 2.13 1.38–3.31 1.46 1.24–1.72
C 1.06 0.94–1.20 1.58 1.28–1.94 2.02 1.28–3.18 1.47 1.24–1.74
CRP (n=5,680) A 1.11 1.03–1.18 1.39 1.22–1.58 1.70 1.28–1.69 1.20 1.08–1.33
B 1.08 1.01–1.16 1.30 1.14–1.49 1.70 1.28–2.25 1.18 1.07–1.31
C 1.08 1.00–1.16 1.32 1.16–1.51 1.63 1.21–2.18 1.19 1.08–1.32
Fibrinogen (n=5,631) A 0.99 0.90–1.10 1.33 1.11–1.58 1.48 1.01–1.61 1.47 1.29–1.68
B 1.01 0.91–1.13 1.20 1.00–1.45 1.45 0.98–2.15 1.46 1.27–1.68
C 1.01 0.91–1.12 1.19 0.99–1.44 1.45 0.97–2.17 1.47 1.27–1.68
Event groupings as defined in the methods. Fatal CVD deaths preceded by nonfatal CVD are excluded. Model A, adjusted for randomized treatment. Model B, adjusted
for randomized treatment, age, gender, LDL cholesterol, HDL cholesterol, systolic blood pressure, current smoker, diabetes, previous CVD (CHD, stroke, peripheral
arterial disease, stroke, and transient ischaemic attack), use of antihypertensive therapy, and country. Model C, Model B+ adjusted for log triglyceride, BMI, diastolic
blood pressure, exsmoker (as well as current smoker).
doi:10.1371/journal.pmed.1000099.t003
Inflammation: Fatal vs Nonfatal CVD Events
PLoS Medicine | www.plosmedicine.org 6 June 2009 | Volume 6 | Issue 6 | e1000099instance, neopterin, a marker of macrophage activation, also
showed trends to be more strongly related to risk of death alone
(HR for upper quarter versus lower three quarters, 1.86 (95% CI
1.24–2.77) versus its association with acute MI (HR 1.35, CI 1.03–
1.79) in a population with prevalent vascular disease [28].
Aetiological Relevance
One interpretation of our findings is a possible mechanistic role
for inflammation in the promotion of serious vascular disease,
which is more likely to lead to death. Inflammation marker levels
are associated with risk of death in the acute setting [29,30], and it
may be that elevated baseline inflammation increases the risk (or is
associated with an increase in risk) that leads to more incident
vascular events being fatal. The mechanisms for this observation
require further study, but could include chronic low-grade
inflammation being associated with a lowered buffering capacity
to cope with the stress of a significant vascular insult, a greater
likelihood of any vascular insult to be accompanied by a fatal
cardiac arrhythmia or more diffuse myocardial necrosis [31], or
indeed a greater clotting potential, or a combination of
mechanisms. The search for such mechanisms will be stimulated
by our findings. Among the inflammatory markers IL-6 seemed to
show more marked associations with fatal CVD than CRP or
fibrinogen, although epidemiological studies alone cannot infer
causality. The recent availability of IL-6 blocking agents in
autoimmune diseases [32] may help promote relevant research in
this area and there is increasing need to test whether inflammation
blockers lessen vascular risk, or otherwise, in a range of differing
populations. Alternatively, inflammatory markers may not be
causally related to vascular death; our findings could also be
consistent with the hypothesis that elevated levels of inflammatory
markers are an indicator of subclinical disease (vascular or
otherwise) and lifestyle circumstances that promote death from
several causes [26]. To this end all inflammatory markers were, as
expected, also independently associated with non-CVD mortality.
Clinical Relevance
CRP as a CVD risk factor is once again in sharp focus post
JUPITER trial [33,34], but there is continued debate about its
inclusion in CVD risk assessment [35]. However, the differential
pattern of association of CRP (and IL-6) with fatal versus nonfatal
events is not at all considered as a potentially important feature in
prior literature, but may need consideration by relevant guideline
committees. For example, recently devised SCORE risk charts for
European-wide use, devised by a European guidelines committee
[36], is designed to predict risk of 10-y CVD fatality rather than
combined fatal and nonfatal CVD. Thus, the use of CRP or other
inflammatory markers in CVD risk assessment, if ever widely
adopted, may well be more suitedto predictionof fatal CVDevents.
For instance, Zethelius et al. recently demonstrated significant
improved ability of four biomarkers including CRP (others NT-
proBNP, cystatin C, and troponin I) to usefully enhance prediction
of CVD death beyond traditional risk factors [37]. However, these
authors appeared not to be aware of the possibility that their
superior predictive results may have been influenced by their use of
only a fatal CVD endpoint. Accordingly, our findings may help
improve future research of novel CVD risk factors for clinical use.
Of course the exploration of our conclusions, if confirmed, should
help also in maintaining future health.
Our findings may also hold particular relevance to patients with
rheumatoid arthritis (RA), a chronic inflammatory condition,
recently shown to be linked to a greater likelihood of sudden death
compared to non-RA patients [38], and a greater 30-d case fatality
rate following MI [39]. Thus, improved understanding of the
mechanisms linking inflammationmarkers to fatal CVDevents may
ultimately improve clinical management not only in the low grade
setting but also in the high grade inflammation arena of auto-
immune conditions. In this respect, IL-6 blocking agents are now
licensedforclinicaluseinRA[32],andarelikelytobeusedinfuture
large trials to tease out causal pathways and net vascular effects.
Generalisability of PROSPER
We examined the dataset for peculiarities that might render our
findings atypical, but found no such evidence. First, the baseline
associations of inflammatory markers with each other and with
other risk factors in this population are broadly in keeping with
expectations. Second, the observed adjusted risk associations of IL-
6 and CRP with the combined nonfatal and fatal CVD endpoint
are broadly consistent with findings from recent important meta-
analyses including younger populations [2,3]. Similarly, PROS-
PER findings on other risk factors (e.g., leptin [40]) or risk criteria
(e.g., metabolic syndrome [41]) are also in line with observational
studies conducted in younger populations [41,42]. Third, our
findings for CRP in terms of modest improvement in prediction of
the traditionally examined combined fatal and nonfatal CVD
endpoint, beyond conventional risk factors, are in line with recent
reports from the Cardiovascular Health study group [10] and the
MONICA Augsburg study [9] where this variable only modestly
improved prediction of CVD events beyond that of conventional
risk factors. Fourth, all three inflammatory markers, measured
independently, showed similar associations. Fifth, our findings for
IL-6 and CRP were similar in unadjusted and adjusted analysis
and thus unlikely to be biased by adjustment by other CVD risk
factors. Sixth, the results were also not influenced by randomized
treatment. Finally, the endpoint ascertainments were of high
quality given that PROSPER was a clinical trial with adjudication
committees with rigorous endpoint criteria.
Study Limitations
Although this is a large study with a large number of events, it
has insufficient power to further analyse the ‘‘fatal other CVD’’
and ‘‘non-CVD mortality’’ groups by subgroups of events such as
MI versus stroke. The study comprised elderly at risk patients
(largely secondary prevention), and we cannot exclude the
possibility that this group may show more marked differences in
the magnitude of association of inflammation markers with fatal
versus nonfatal CVD events as compared with studies in middle-
aged populations, although, as discussed above, the extent of other
data suggests PROSPER findings are generally consistent with
those in younger cohorts. Although PROSPER is a high vascular
risk population, participants were otherwise clinically healthy, as
per trial exclusion criteria (e.g., no diagnosed prevalent cancers at
baseline [21,22]). The study only had up to an average of 3.2-y
follow-up, although short follow-up may be appropriate in elderly
populations. We recognize the study is more relevant to reveal
novel associations rather than test prediction but nevertheless, on
the basis of our findings others should now retest their risk factor
data to check for differential prediction of fatal versus nonfatal
events. The study was conducted in the context of a randomized
trial of statins [22]—however, there was no interaction between
active and placebo group status for the main analyses in the
present report. We did not adjust for regression dilution because of
lack of repeat measurement for parameters but note that IL-6
associations with fatal CVD events in particular may be
considerably strengthened since this molecule exhibits greater
intra-individual variability in its circulating concentrations than
does CRP. In this regard, that baseline IL-6 levels demonstrated
the greatest differential association between fatal and nonfatal
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significance. IL-6 is also a more credible causal factor for vascular
disease than is CRP. Finally, we recognise that although our
findings were consistent for all three inflammatory markers, others
will need to replicate our work in prospective cohorts that have all
the required endpoints and baseline measurements. In addition,
further validation by meta-analysis [43] may soon be possible,
whereas Mendelian randomization techniques could be used to
examine for potential causal associations [44,45].
Conclusion
We show that three markers of low grade inflammation (in
particular IL-6 and CRP), are more strongly associated with fatal
CVD events than nonfatal vascular events. This novel observation
has potentially important aetiological and clinical implications.
Future studies should, wherever possible, systematically compare
and contrast risk associations of biomarkers (new and old) with
fatal versus nonfatal CVD events.
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Background. Cardiovascular disease (CVD)—disease that
affects the heart and/or the blood vessels—is a common
cause of death in developed countries. In the USA, for
example, the leading cause of death is coronary heart
disease (CHD), a CVD in which narrowing of the heart’s blood
vessels by ‘‘atherosclerotic plaques’’ (fatty deposits that build
up with age) slows the blood supply to the heart and may
eventually cause a heart attack (myocardial infarction). Other
types of CVD include stroke (in which atherosclerotic plaques
interrupt the brain’s blood supply) and heart failure (a
condition in which the heart cannot pump enough blood to
the rest of the body). Smoking, high blood pressure, high
blood levels of cholesterol (a type of fat), having diabetes,
and being overweight all increase a person’s risk of
developing CVD. Tools such as the ‘‘Framingham risk
calculator’’ take these and other risk factors into account
to assess an individual’s overall risk of CVD, which can be
reduced by taking drugs to reduce blood pressure or
cholesterol levels (for example, pravastatin) and by making
lifestyle changes.
Why Was This Study Done? Inflammation (an immune
response to injury) in the walls of blood vessels is thought to
play a role in the development of atherosclerotic plaques.
Consistent with this idea, several epidemiological studies
(investigations of the causes and distribution of disease in
populations) have shown that people with high circulating
levels of markers of inflammation such as interleukin-6 (IL-6),
C-reactive protein (CRP), and fibrinogen are more likely to
have a stroke or a heart attack (a CVD event) than people
with low levels of these markers. Although these studies
have generally lumped together fatal and nonfatal CVD
events, some evidence suggests that circulating
inflammatory markers may be more strongly associated
with fatal than with nonfatal CVD events. If this is the case,
the mechanisms that lead to fatal and nonfatal CVD events
may be subtly different and knowing about these differences
could improve both the prevention and treatment of CVD. In
this study, the researchers investigate this possibility using
data collected in the Prospective Study of Pravastatin in the
Elderly at Risk (PROSPER; a trial that examined pravastatin’s
effect on CVD development among 70–82 year olds with
pre-existing CVD or an increased risk of CVD because of
smoking, high blood pressure, or diabetes).
What Did the Researchers Do and Find? The researchers
used several statistical models to examine the association
between baseline levels of IL-6, CRP, and fibrinogen in the
trial participants and nonfatal CVD events (nonfatal heart
attacks and nonfatal strokes), fatal CVD events, death from
other types of CVD, and deaths from other causes during 3.2
years of follow-up. Increased levels of all three inflammatory
markers were more strongly associated with fatal CVD than
with nonfatal CVD after adjustment for treatment allocation
and for other established CVD risk factors but this pattern
was strongest for IL-6. Thus, a unit increase in the log of IL-6
levels increased the risk of fatal CVD by half but increased
the risk of nonfatal CVD by significantly less. The researchers
also investigated whether including these inflammatory
markers in tools designed to predict an individual’s CVD
risk could improve the tool’s ability to distinguish between
individuals with a high and low risk. The addition of IL-6 to
established risk factors, they report, increased this
discriminatory ability for fatal CVD but not for nonfatal CVD.
What Do These Findings Mean? These findings indicate
that, at least for the elderly at-risk patients who were
included in PROSPER, inflammatory markers are more
strongly associated with the risk of a fatal heart attack or
stroke than with nonfatal CVD events. These findings need to
be confirmed in younger populations and larger studies also
need to be done to discover whether the same association
holds when fatal heart attacks and fatal strokes are
considered separately. Nevertheless, the present findings
suggest that inflammation may specifically help to promote
the development of serious, potentially fatal CVD and should
stimulate improved research into the use of inflammation
markers to predict risk of deaths from CVD.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000099.
N The MedlinePlus Encyclopedia has pages on coronary heart
disease, stroke, and atherosclerosis (in English and Spanish)
N MedlinePlus provides links to many other sources of
information on heart diseases, vascular diseases, and
stroke (in English and Spanish)
N Information for patients and caregivers is provided by the
American Heart Association on all aspects of cardiovascular
disease, including information on inflammation and heart
disease
N Information is available from the British Heart Foundation
on heart disease and keeping the heart healthy
N More information about PROSPER is available on the Web
site of the Vascular Biochemistry Department of the
University of Glasgow
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